Tatva Chintan Makes Blockbuster Debut Doubling Investors Money

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jul 29, 2021 - Tatva Chintan Makes Blockbuster Debut Doubling Investors Money

Tatva Chintan Makes Blockbuster Debut Doubling Investors Money

Jul 29, 2021

Specialty chemical manufacturer Tatva Chintan Pharma Chem made its stock market debut on Thursday by listing at Rs 2,111.9 per share on the NSE, a 95% premium over issue price of Rs 1,083 a piece.

On BSE, the scrip got listed at Rs 2,111.8, up 95%.

Further, the shares of Tatva Chintan Pharma extended rally after stellar debut, rising as much as 129.6% to hit a day's high of Rs 2,486.3 on the BSE.

The strong listing was in line with the recent trend, wherein market debutants have delivered 50-100% returns at listing.

To name a few, G R Infraprojects saw a stellar 105% listing gain on 19 July while Clean Science, which debuted on the same day, witnessed a 98.3% listing pop.

Zomato got listed at a 52% premium on 23 July.

--- Advertisement ---
Click Here to Watch the Replay of the Great Indian Wealth Project Event

At our Great Indian Wealth Project special event, we gave away these valuable resources virtually FREE.

This bundle includes our comprehensive wealth creation guide titled- Eight Steps to Your Eight Figure Fortune

And 3 high-potential stocks covered in our latest special reports...

To immediately get you started towards accumulating Rs 7 crore in wealth over the long-term

If you missed this event for some reason, then you can watch the special replay of this event.

Click Here to Watch the Replay...

Company received healthy response from investors

Its initial public offering (IPO) had opened for subscription on 16 July and closed on 20 July, and the share allotment was finalised on Tuesday.

The Rs 5 bn IPO, saw strong demand. Overall, the issue was subscribed over 180 times. The quota reserved for qualified institutional buyers (QIBs) was subscribed 185.23 times. The quota reserved for non-institutional investors (NIIs) was subscribed 512.22 times. The retail quota was subscribed 35.35 times.

Utilisation of funds raised through public issue

Proceeds from the fresh issue would be used towards funding capital expenditure requirements for expansion of the company's Dahej manufacturing facility.

Also it will be used for up-gradation of a research and development facility in Vadodara, and general corporate purposes.

Watch Now: A Massive 15x Opportunity in Electric Vehicles

Financial snapshot of the company

In terms of revenues and profitability, the company has delivered good performance on both fronts.

It has increased revenues at a compound annual growth rate (CAGR) of 21.7% during the last three fiscals, from Rs 2,068 m in 2019 to Rs 3,062.9 m in 2021.

The bottomline has grown at a CAGR of 59.5%, from Rs 205.4 m in 2019 to Rs 522.6 m in 2021.

Key Parameters

(Rs m) FY19 FY20 FY21
Revenues 2,068 2,646 3,063
Revenue Growth - 28% 15.7%
Expenses 1,802 2,170 2,456
Net Profit 205 378 523
Net Profit Margin (%) 9.9% 14.3% 17.1%
Net Worth 797 1,177 1,660
Return on Equity (ROE) 388% 311% 318%
Data Source: Company's Red Herring Prospectus (RHP)

With decent financial position, the company is able to invest in capital expenditure. In fiscal 2021, the company incurred Rs 26.5 m worth of capital expenditure.

That apart, at the issue price, the Tatva Chintan commanded a P/E of 41.6 times and a market-cap of Rs 24 bn compared with listed peers Aarti Industries 63 times and Navin Fluorine International at 61.4 times.

Tatva Chintan's IPO grey market premium ahead of listing

The chemical company Tatva Chintan Pharma Chem shares traded at more than 100% premium in the grey market, ahead of its listing.

The stellar IPO subscription, leading position in manufacturing of structure-directing agents for zeolites in India, healthy financials and return ratios, and high quality product portfolio were the key reasons for hefty grey market premium.

--- Advertisement ---
REVEALED: How to Grow and Protect Your Wealth in 2022 and Beyond...

Interested in growing and protecting your wealth in the next decade?

Then Register for The Equitymaster Conference 2022 Right Now

Where the top investment minds of this generation will reveal their most lucrative money-making investment and wealth-protection strategies for the next decade.

Click Here to Get More Details...

Tatva Chintan shares traded at a premium of Rs 1,000-1,100 per share in the grey market, the IPO Watch and IPO Central showed.

This resulted in a price of Rs 2,083-2,183, a premium of 92.3%-101.6% over the final issue price of Rs 1,083 per share.

The grey market is an unofficial platform, wherein IPO shares traded till the listing of a company on the bourses.

About the company

Tatva Chintan Pharma Chem is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.

The company was incorporated in 1996 and is among the largest manufacturers of SDAs for zeolites in India.

It serves customers across industries i.e. automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical, personal care, and others.

Its products are not only sold in India but also export to more than 25 countries all over the world.

Owing to shutdowns in China and lack of capacity additions in other developed countries, India stands to benefit in the export market.

Chemical sector IPOs

The pandemic has been a blessing in disguise for the chemical sector.

The stalling of imports from China in the last year translated to more buyers in India, who were otherwise buying from China.

This will be the fifth IPO by a chemical company in the past year after Rossari Biotech, Chemcon Specialty Chemicals, Anupam Rasayan, and the recently concluded Clean Science IPO.

The public issue of Clean Science and Technology saw a blockbuster response from investors, especially from QIBs and non-institutional investors.

All the four specialty chemical stocks presently are trading significantly higher than their issue prices.

Shares of recently listed company Clean Science is trading at Rs 1,622 from its issue price of Rs 900, up 80%.

Rossari Biotech is trading at Rs 1,221.3 compared to its issue price of Rs 425, up 187%.

Chemcon Specialty Chemicals is trading at Rs 511.8 compared to its issue price of Rs 340, up 51%.

Meanwhile, Anupam Rasayan is up 31% compared with its issue price of Rs 555.

Given the rising demand for speciality chemicals, the outlook for the sector remains promising.

Indian manufacturers have benefited from a rise in demand from global customers who aim to reduce dependence on China.

How the stock of Tatva Chintan Pharma Chem performs going ahead remains to be seen.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Tatva Chintan Makes Blockbuster Debut Doubling Investors Money". Click here!


More Views on News

What Next for Devyani, Zomato, & Tatva Chintan Pharma After Stellar IPO Gains? (Views On News)

Aug 20, 2021

What's the outlook for Devyani, Zomato, and Tatva Chintan Pharma after robust listings?

Ami Organics Stock Makes Impressive Debut on Bourses. Lists at 49% Premium (Views On News)

Sep 14, 2021

Shares of Ami Organics makes a strong debut on the stock exchange. Did you bid for the IPO?

Chemplast Sanmar Makes Flat Debut as IPO Frenzy Fizzles Out (Views On News)

Aug 24, 2021

The grey market had indicated a flat listing for shares of Chemplast Sanmar ahead of its debut.

Understanding Aarti Industries' Demerger (Views On News)

Aug 20, 2021

Will the pharma unit's demerger unlock value for shareholders?

Pidilite Results Review: Net Profit Spikes as Sales Rise 121% (Views On News)

Aug 12, 2021

Pidilite posts strong sales growth and a multi-fold jump in bottomline.

More Views on News

Most Popular

All You Need to Know About Primary and Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year (Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 8, 2021 (Close)


  • Track your investment in TATVA CHINTAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks